Arikayce (Amikacin Liposomal/Neb.Accessr) Patent Expiration, LOE Window & CMS Spending

Arikayce (Amikacin Liposomal/Neb.Accessr) by Insmed Incorpor: Off-Patent Genericized (AB Competition), 0 AB generics, $202.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorInsmed Incorpor
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$202.0M
2024 Medicare Part D Spend$187.1M
2024 Medicaid Spend$14.9M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 24.2% 2-yr change)